hVIVO Trading Update: FY23 revenue p 15% to £56m, with EBITDA margin expansion

Monitoring is essential from the moment a clinical trial is planned until it concludes. This ensures that the study remains unbiased, patient safety is prioritised, and accurate results are achieved. The process of clinical trial monitoring

hVIVO, an Irish research and clinical trial specialist, saw its revenues increase by over 30% in the first six months of the year, reaching £35.6 million. Previously known as Open Orphan, the company reported a significant

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

Testing new treatments and vaccines often requires years, if not decades, to gather sufficient data. In response, scientists are turning to a more direct approach that involves deliberately infecting volunteers with potentially deadly pathogens. A notable

Specialist research group hVIVO has seen a significant rise in revenue for the first half of 2024, recording a 30.6% increase compared to the same period last year. The company generated £35.6 million in the first

Clinical trials play a pivotal role in advancing the medical industry by allowing new treatments and interventions to be rigorously tested for both effectiveness and safety. Understanding how clinical trial data is used is essential to

Hvivo, previously known as Open Orphan, saw a significant increase in earnings during the first six months of the year, marking a 67.6% rise. Earnings before interest, taxes, depreciation, and amortisation reached £8.7 million (€10.32 million),

hVIVO, a UK-based company, is leading the development of a platform using human disease models to speed up drug discovery, particularly in respiratory and infectious diseases such as flu, respiratory syncytial virus (RSV), asthma, and the

hVIVO plc, a specialist contract research organisation (CRO), is experiencing rapid growth, establishing itself as the global leader in testing vaccines and therapeutics for infectious and respiratory diseases. By conducting human challenge clinical trials, the company

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

Understanding the distinction between clinical trials and clinical studies is vital in the realm of medical research. While all clinical trials fall under the broader category of clinical studies, the two are not synonymous. Clinical trials

Volunteers are indispensable in clinical trials, and their informed consent serves as the cornerstone of ethical research. This consent is not merely a formality; it represents an ongoing conversation between the research team and participants. The

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

Clinical trials are essential in bringing new drugs, treatments, and interventions to market. These trials progress through several phases, with each stage serving a specific purpose. In the early phases, particularly the first phase, healthy volunteers

When you volunteer for a clinical trial, it’s essential to manage your expectations, understanding both the potential benefits and risks involved. Awareness of the side effects associated with clinical trials can better prepare you for the